CTOs on the Move

Trellis Bioscience

www.trellisbio.com

 
Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

MouldWorks

MouldWorks is a Beulah, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delaware BioScience Association

Delaware BioScience Association has a broad-based membership including pharmaceutical, biotechnology, medical devices, analytical equipment and agricultural products; as well as representatives from academia, medical research, workforce training and other supporting organizations (financial, legal, marketing, consulting, engineering and construction, etc.) that serve the bioscience community. Delaware Bio is focused on being a unified voice for Delaware and the region`s bioscience community to accelerate the growth of human, animal, plant, and industrial biosciences.

Galenea Corp

Galenea Corp is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vizgen

Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.

Northwest Biotherapeutics

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio`s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company`s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company`s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.